Clene’s new clinical data claims to improve brain energy metabolism

Image Credit: Symbiosys Capital Management

Announcement

The Clene Inc., and its fully owned subsidiary Clene Nanomedicine Inc., a leading clinical stage biopharmaceutical company that targets mitochondrial health improvement and provides a safe space for neuronal function, has unveiled its presentation of the merged REPAR-MS results. The results are across non-active progressive MS and relapsing one, held on September 24-26, 2025, in Barcelona, Spain, during its 41st congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

REPAIR Studies Insights

The REPAIR studies, involving REPAIR-MS and REPAIR-PD, were sequential group, open-label, investigator fusion phase 2 studies of the magnetic resonance spectroscopy (P-MRS) to examine the impact of CNM-Au8 on the bioenergetic enhancement of impaired neuronal redox state. The participants went through 12 weeks of CNM-Au8, chained by a 6-week post-therapy safety follow-up for REPAIR-MS. The main consideration was the difference in the brain NAD+/NADH ratio, which is a measure of energetic capacity directly from baseline to week 12.

The participants examined for the initial efficacy outcome were post-baseline scan evaluable at the week 12 visit involving REPAIR-MS cohort 1, 2, and REPAIR-PD in pre-specified analyses throughout the overall population. The major findings from the CNM-Au8 treatment consist of different ratios as per the study and enrollment of the participants, demonstrating measures and impact in the fraction, respectively. The exercised connection between brain energy metabolic indices and MS disease activity was there at the pre-treatment baseline visit.

The expanded disability status scale (EDSS), a worldwide measure of MS disease severity, was prominently connected with the baseline deficits in the NAD+/NADH ratio. Other baseline measures of working memory, upper extremity function, and cognitive processing speed results are on the site mentioned at the end of the news. This data encompasses the insight that bioenergetic failure in the brain is a major contributor to disease progression in MS and neurodegeneration.

MD, Head of Medical at Clene, Benjamin Greenberg said, “The CNM-Au8 was able to elaborate an improvement in the metabolic profiles in the brain in around 12 weeks, showing its capability of CNM-Au8 to identify the major energy deficits in the brain. These results elaborate on the potential of CNM-Au8 to rescue this deficit along describe the direct correlation of brain bioenergetics with disability. The analysis is in progress to provide a detailed analysis of progressive MS and might also show how focusing on brain bioenergetics can cure MS and various other neurodegenerative disorders.”